Expectations Surging for Marinus Pharma (MRNS) Trial Data; Regulus Therapeutics (RGLS) Crashes On FDA’s Determination


Shares of Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) soared over 20% in after-hour trading as the company said that it will release on Tuesday, June 28 – before the opening bell – results from a phase 2 exploratory trial examining its CNS-selective GABAA modulator Ganaxolone in children with Fragile X Syndrome, an inherited form of intellectual disability

MRNS stock finished the regular session at $1.24, down $0.10 (or -7.46%) with a total volume of 338,676 shares traded on Monday

Marinus Pharmaceuticals, which focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders, has 19.51M Shares Outstanding, Market Capitalization (intraday) of $24.19M and MRNS stock 52-week range is between $1.19 and $20.72 per share



Regulus Therapeutics Inc. (Nasdaq:RGLS) shares slumped more than 50% to touch a new 52-week low in the extended session Monday as the biopharmaceutical company said that the U.S. Food and Drug Administration (FDA) has placed on clinical hold its Investigational New Drug (IND) for RG-101 – Regulus’ treatment for chronic HCV infection

RGLS stock closed in negative territory by 5.29% (or -$0.28) at $5.01 and 1.35M of its shares changed hands during the day, a large increase in activity versus its average volume (3m) of 794,360

Regulus Therapeutics, which focuses on discovering and developing drugs that target microRNAs to treat a range of diseases, has 52.78M Shares Outstanding. At close on Monday, the company had a Market Capitalization $243.70M and RGLS stock one-year range was from $4.82 to $5.35 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/